NASDAQ:JUNOJuno Therapeutics Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Juno Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Share Today's Range N/A50-Day Range$86.96MA: $86.96▼$86.9652-Week Range N/AVolume2 shsAverage Volume5.48 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Juno Therapeutics. Previous Next 2.7 Community Rank Outperform VotesJuno Therapeutics has received 496 “outperform” votes. (Add your “outperform” vote.)Underperform VotesJuno Therapeutics has received 413 “underperform” votes. (Add your “underperform” vote.)Community SentimentJuno Therapeutics has received 54.57% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Juno Therapeutics and other stocks. Vote “Outperform” if you believe JUNO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe JUNO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldJuno Therapeutics does not currently pay a dividend.Dividend GrowthJuno Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Juno Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 15.08% of the stock of Juno Therapeutics is held by insiders.Percentage Held by Institutions70.19% of the stock of Juno Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.74 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorN/A Current SymbolNASDAQ:JUNO Previous Symbol CUSIPN/A CIK1594864 Webwww.junotherapeutics.com Phone+1-206-5821600Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableOptionable Receive JUNO News and Ratings via Email Sign-up to receive the latest news and ratings for JUNO and its competitors with MarketBeat's FREE daily newsletter. Juno Therapeutics (NASDAQ:JUNO) Frequently Asked Questions How were Juno Therapeutics' earnings last quarter? Juno Therapeutics Inc (NASDAQ:JUNO) announced its quarterly earnings data on Wednesday, November, 1st. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.80) by $0.07. The biopharmaceutical company earned $44.80 million during the quarter, compared to the consensus estimate of $18.12 million. The firm's revenue for the quarter was up 115.4% compared to the same quarter last year. During the same quarter last year, the company earned ($0.57) EPS. View Juno Therapeutics' earnings history. Has Juno Therapeutics been receiving favorable news coverage? News stories about JUNO stock have trended extremely negative on Tuesday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Juno Therapeutics earned a daily sentiment score of -4.8 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutJuno Therapeutics. What other stocks do shareholders of Juno Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Juno Therapeutics investors own include Celgene (CELG), Kite Pharma (KITE), bluebird bio (BLUE), Gilead Sciences (GILD), Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), TherapeuticsMD (TXMD), Alibaba Group (BABA) and Heritage-Crystal Clean (HCCI). Who are Juno Therapeutics' key executives? Juno Therapeutics' management team includes the following people: Howard H. Pien, Independent Chairman of the Board (Age 59)Hans Edgar Bishop, President, Chief Executive Officer, Director (Age 53)Sunil Agarwal M.D., President of Research & Development (Age 47)Steven D. Harr M.D., Chief Financial Officer, Head of Corporate Development (Age 46)Hyam I. Levitsky M.D, Executive vice president - Research, chief scientific officer (Age 54)Robert W. Azelby, Executive Vice President, Chief Commercial Officer (Age 49)Ann Lee Ph.D., Executive Vice President - Technical OperationsPatrick Y. Yang, Executive Vice President (Age 69)Cynthia Elkins, Chief Information OfficerBernard J. Cassidy, General Counsel, Secretary (Age 62) When did Juno Therapeutics IPO? (JUNO) raised $153 million in an IPO on Friday, December 19th 2014. The company issued 9,300,000 shares at a price of $15.00-$18.00 per share. Morgan Stanley, J.P. Morgan and Goldman Sachs acted as the underwriters for the IPO and Leerink Partners was co-manager. What is Juno Therapeutics' stock symbol? Juno Therapeutics trades on the NASDAQ under the ticker symbol "JUNO." What is Juno Therapeutics' official website? The official website for Juno Therapeutics is www.junotherapeutics.com. How can I contact Juno Therapeutics? Juno Therapeutics' mailing address is 400 Dexter Ave N Ste 1200, SEATTLE, WA 98109-4703, United States. The biopharmaceutical company can be reached via phone at +1-206-5821600. This page was last updated on 5/26/2020 by MarketBeat.com Staff
